Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome,
can progress to steatohepatitis (NASH) and advanced liver damage, such as that from liver …

The incidence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH) has increased in parallel with the incidence of obesity. While both NAFLD and …

Background A sedentary lifestyle and poor diet are risk factors for the progression of non-
alcoholic fatty liver disease. However, the pathogenesis of hepatic lipid accumulation is not …

Background Nonalcoholic fatty liver disease (NAFLD) is a major public health concern in
western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is …

Obese and type 2 diabetic (T2DM) patients have a high prevalence of nonalcoholic fatty liver
disease (NAFLD). NAFLD is a continuum of chronic liver diseases ranging from benign …

Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in
obesity and type 2 diabetes, and is associated with reduced hepatic omega-3 …

Background & Aims n‐3 polyunsaturated fatty acids (PUFA) ameliorate fatty liver in
experimental models, but their effects on inflammation and fibrosis during steatohepatitis are …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the
Western world. Its prevalence has increased with the growing obesity epidemic, yet no …

Omega-3 (n-3) long-chain polyunsaturated fatty acids (n-3 LCPUFA) are associated with
several physiological functions, suggesting that their administration may prevent non …

The prevalence of nonalcoholic fatty liver disease (NAFLD) has dramatically increased
globally during recent decades. Intake of n‐3 polyunsaturated fatty acids (PUFAs), mainly …